Wei Li

AstraZeneca (United Kingdom) ORCID: 0009-0009-2049-8372

1

h-index

1

Publications

2,014

Citations

Publications

1 shown

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Frequent Co-Authors

Luis Paz‐Ares

Université Toulouse III - Paul Sabatier

Mikhail Dvorkin

Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"

Yuanbin Chen

Hematology Oncology Consultants

Niels Reinmuth

Asklepios Fachkliniken München-Gauting

Katsuyuki Hotta

Okayama University Hospital

Dmytro Trukhin

Odessa National Medical University

Researcher Info

h-index: 1
Publications: 1
Citations: 2,014
Institution: AstraZeneca (United Kingdom)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0009-0009-2049-8372

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.